Kiniksa Pharmaceuticals International (KNSA) Total Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Total Liabilities for 10 consecutive years, with $242.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 45.63% year-over-year to $242.0 million; the trailing twelve-month figure through Jun 2026 stood at $242.0 million (up 45.63% YoY), and the FY2025 full-year result was $196.0 million, up 37.93% from the prior year.
• Total Liabilities grew to $242.0 million in Q2 2026 per KNSA's latest filing, from $219.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $242.0 million in Q2 2026 and bottomed at $52.8 million in Q1 2023.
• Historically, Total Liabilities has averaged $119.5 million across 5 years, with a median of $97.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 95.68% in 2022, then dropped 18.47% in 2023.
• Over 5 years, Total Liabilities stood at $63.5 million in 2022, then soared by 37.72% to $87.5 million in 2023, then surged by 62.45% to $142.1 million in 2024, then surged by 37.93% to $196.0 million in 2025, then grew by 23.43% to $242.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $242.0 million, $219.6 million, and $196.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.